Beyond hepatoprotection: a meta-analysis quantifying the cardiovascular benefit of antidiabetic drugs in patients with metabolic dysfunction-associated steatohepatitis
Metabolic dysfunction-associated steatohepatitis (MASH), the progressive form of metabolic dysfunction-associated steatotic liver disease (MASLD), is associated with substantially elevated cardiovascular risk, yet the cardiovascular efficacy of antidiabetic drugs in this population has not been systematically quant...